{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:40:01Z","timestamp":1761489601133,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":3290,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.7861\/clinmedicine.15-2-155","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T09:20:15Z","timestamp":1427707215000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug therapies in older adults (part 2)"],"prefix":"10.1016","volume":"15","author":[{"given":"Omar","family":"Mukhtar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen HD","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","series-title":"Modelling the UK burden of cardiovascular disease to 2020: A research report for the Cardio & Vascular Coalition and the British Heart Foundation.","author":"Capewell","key":"10.7861\/clinmedicine.15-2-155_bib1"},{"key":"10.7861\/clinmedicine.15-2-155_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autneu.2011.02.004","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"161","author":"Freeman","year":"2011","journal-title":"Auton Neurosc"},{"key":"10.7861\/clinmedicine.15-2-155_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2217\/1745509X.2.3.505","article-title":"Orthostatic hypotension in older patients","volume":"2","author":"Mader","year":"2006","journal-title":"Aging Health"},{"key":"10.7861\/clinmedicine.15-2-155_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1532-5415.1996.tb03738.x","article-title":"Postural hypotension and dizziness in a general aged population: a four-year follow-up of the Helsinki Aging Study","volume":"44","author":"Tilvis","year":"1996","journal-title":"J Am Geriatr Soc"},{"key":"10.7861\/clinmedicine.15-2-155_bib5","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.1997.03540400049030","article-title":"Patterns of orthostatic BP change and their clinical correlates in a frail elderly population","volume":"277","author":"Ooi","year":"1997","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.15-2-155_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.amjmed.2008.10.040","article-title":"Hypotension un-awareness in profound orthostatic hypotension","volume":"122","author":"Arbogast","year":"2009","journal-title":"Am J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1161\/01.CIR.98.21.2290","article-title":"Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program","volume":"98","author":"Masaki","year":"1998","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.15-2-155_bib8","first-page":"48","article-title":"Postural hypertension in elderly men \u2013 the Honolulu Heart Program","volume":"59","author":"Alagiakrishnan","year":"2000","journal-title":"Hawaii Med J"},{"key":"10.7861\/clinmedicine.15-2-155_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MJT.0b013e31828bfb7f","article-title":"A review of the etiology, associated comorbidities, and treatment of orthostatic hypotension","volume":"20","author":"Perlmuter","year":"2013","journal-title":"Am J Ther"},{"key":"10.7861\/clinmedicine.15-2-155_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1586\/erc.12.11","article-title":"Identification and management of orthostatic hypotension in older and medically complex patients","volume":"10","author":"Mader","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.7861\/clinmedicine.15-2-155_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/ijcp.12122","article-title":"A systematic review of the pharmacological management of orthostatic hypotension","volume":"67","author":"Ong","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.7861\/clinmedicine.15-2-155_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40265-013-0097-0","article-title":"Management of neurogenic orthostatic hypotension in patients with autonomic failure","volume":"73","author":"Schroeder","year":"2013","journal-title":"Drugs"},{"key":"10.7861\/clinmedicine.15-2-155_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ageing\/afs061","article-title":"Efficacy of treatments for orthostatic hypotension: a systematic review","volume":"41","author":"Logan","year":"2012","journal-title":"Age Ageing"},{"key":"10.7861\/clinmedicine.15-2-155_bib14","doi-asserted-by":"crossref","unstructured":"14, European Society of Cardiology. Guidelines for the diagnosis and management of syncope, (2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009;30:2631\u201371.","DOI":"10.1093\/eurheartj\/ehp298"},{"key":"10.7861\/clinmedicine.15-2-155_bib15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1468-1331.2006.01512.x","article-title":"EFNS guidelines on the diagnosis and management of orthostatic hypotension","volume":"13","author":"Lahrmann","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.7861\/clinmedicine.15-2-155_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02291388","article-title":"Fludrocortisone and sleeping in the head-up position limit the postural decrease in CO in autonomic failure","volume":"10","author":"van Lieshout","year":"2000","journal-title":"Clin Auton Res"},{"key":"10.7861\/clinmedicine.15-2-155_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM197907123010202","article-title":"Mineralocorticoid-induced hypertension in patients with orthostatic hypotension","volume":"301","author":"Chobanian","year":"1979","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.15-2-155_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2337\/diab.24.4.381","article-title":"9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy","volume":"24","author":"Campbell","year":"1975","journal-title":"Diabetes"},{"key":"10.7861\/clinmedicine.15-2-155_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02291388","article-title":"Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure","volume":"10","author":"van Lieshout","year":"2000","journal-title":"Clin Auton Res"},{"key":"10.7861\/clinmedicine.15-2-155_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2796.1992.tb00563.x","article-title":"Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisones","volume":"232","author":"ten Harkel","year":"1992","journal-title":"J Intern Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib22","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1055\/s-0028-1106461","article-title":"Fludrocortisone in the treatment of orthostatic hypotension: ophthalmodynamography during standing","volume":"100","author":"Finke","year":"1975","journal-title":"Dtsch Med Wochenschr"},{"key":"10.7861\/clinmedicine.15-2-155_bib23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1517\/14656566.1.4.835","article-title":"Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension","volume":"1","author":"Cruz","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.7861\/clinmedicine.15-2-155_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.mpmed.2010.06.005","article-title":"Heart failure: epidemiology, investigation and management","volume":"38","author":"Gardner","year":"2010","journal-title":"Medicine"},{"key":"10.7861\/clinmedicine.15-2-155_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1053\/euhj.1998.1280","article-title":"Incidence and aetiology of heart failure: a population-based study","volume":"20","author":"Cowie","year":"1999","journal-title":"Eur Heart J"},{"year":"2012","series-title":"Coronary heart disease statistics 2012","author":"Townsend","key":"10.7861\/clinmedicine.15-2-155_bib26"},{"key":"10.7861\/clinmedicine.15-2-155_bib27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/heart.83.5.596","article-title":"Epidemiology, aetiology, and prognosis of heart failure","volume":"83","author":"McMurray","year":"2000","journal-title":"Heart"},{"key":"10.7861\/clinmedicine.15-2-155_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib31","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.15-2-155_bib32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2000","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.15-2-155_bib34","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/eurheartj\/ehn476","article-title":"Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure\u2013Assessment of Reduction in Mortality and morbidity programme","volume":"29","author":"Cohen-Solal","year":"2008","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.15-2-155_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.15-2-155_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib37","first-page":"2312","article-title":"Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"ATLAS Study Group. Circulation"},{"key":"10.7861\/clinmedicine.15-2-155_bib38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.15-2-155_bib40","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.15-2-155_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.15-2-155_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjcard.2004.11.052","article-title":"Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials","volume":"95","author":"Dulin","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.7861\/clinmedicine.15-2-155_bib43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5694\/mja12.10993","article-title":"Management of heart failure","volume":"199","author":"Krum","year":"2013","journal-title":"Med J Aust"},{"key":"10.7861\/clinmedicine.15-2-155_bib44","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Eng J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib48","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJMcp070677","article-title":"Gynecomastia","volume":"357","author":"Braunstein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.15-2-155_bib49","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective I(f) current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease","volume":"64","author":"DiFrancesco","year":"2004","journal-title":"Drugs"},{"year":"2012","series-title":"Ivabradine for the treatment of chronic heart failure: A Single Technology Appraisal","author":"Edwards","key":"10.7861\/clinmedicine.15-2-155_bib50"},{"key":"10.7861\/clinmedicine.15-2-155_bib51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.15-2-155_bib52","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","article-title":"(SHIFT Investigators). Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study","volume":"15","author":"Tavazzi","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.7861\/clinmedicine.15-2-155_bib53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.HYP.0000146483.78994.56","article-title":"Neutral endo-peptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition","volume":"44","author":"Cruden","year":"2004","journal-title":"Hypertension"},{"key":"10.7861\/clinmedicine.15-2-155_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/cs0910283","article-title":"Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure","volume":"91","author":"Rademaker","year":"1996","journal-title":"Clin Sci (Lond)"},{"key":"10.7861\/clinmedicine.15-2-155_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.0306-5251.2001.1420.x","article-title":"Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP)","volume":"52","author":"Wilkinson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.7861\/clinmedicine.15-2-155_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000092457","article-title":"Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase","volume":"103","author":"Maric","year":"2006","journal-title":"Nephron Physiol"},{"key":"10.7861\/clinmedicine.15-2-155_bib57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00395-004-0460-0","article-title":"Molecular physiology of natriuretic peptide signalling","volume":"99","author":"Kuhn","year":"2004","journal-title":"Basic Res Cardiol"},{"key":"10.7861\/clinmedicine.15-2-155_bib58","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J Hypertens"},{"key":"10.7861\/clinmedicine.15-2-155_bib59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00005344-199801000-00017","article-title":"Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II","volume":"31","author":"Rademaker","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.7861\/clinmedicine.15-2-155_bib60","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/00005344-199912000-00003","article-title":"Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril","volume":"34","author":"Trippodo","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.7861\/clinmedicine.15-2-155_bib61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.7861\/clinmedicine.15-2-155_bib62","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.15-2-155_bib63","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"(PARADIGM-HF Investigators and Committees). Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824019821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824019821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.15-2-155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:35:21Z","timestamp":1761460521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824019821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1470211824019821"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.15-2-155","relation":{},"ISSN":["1470-2118"],"issn-type":[{"type":"print","value":"1470-2118"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug therapies in older adults (part 2)","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.15-2-155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2015. All rights reserved.","name":"copyright","label":"Copyright"}]}}